Pulse Biosciences, Inc (PLSE) News

Pulse Biosciences, Inc (PLSE): $15.77

0.41 (-2.53%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Filter PLSE News Items

PLSE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PLSE News Highlights

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

  • 404 Page not found

    Error: Page not found

    The requested URL was not found on this server.

Latest PLSE News From Around the Web

Below are the latest news stories about PULSE BIOSCIENCES INC that investors may wish to consider to help them evaluate PLSE as an investment opportunity.

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

MIAMI, January 10, 2025--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced the appointment of Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer.

Yahoo | January 10, 2025

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

MIAMI, January 03, 2025--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

Yahoo | January 3, 2025

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

HAYWARD, Calif., December 23, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, to redeem the first tranche of common stock warrants, redeemable by the Company if the Company’s stock trading price exceeds $16.50 for twenty consecutive trading days, that were issued as part of it

Yahoo | December 23, 2024

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

HAYWARD, Calif., December 19, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that, on December 18, 2024, the Company’s Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company’s 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of C

Yahoo | December 19, 2024

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

MIAMI, December 17, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This preclinical study demonstrates the advantages of the nano-PFA Cardiac Surgical System over radiofrequency technology for the ablation of cardiac tissue.

Yahoo | December 17, 2024

Robert Duggan Spends US$972k On Pulse Biosciences Stock

Those following along with Pulse Biosciences, Inc. ( NASDAQ:PLSE ) will no doubt be intrigued by the recent purchase of...

Yahoo | December 16, 2024

Top Key Executive Robert Duggan, Pulse Biosciences, Inc.'s (NASDAQ:PLSE) largest shareholder sees value of holdings go down 13% after recent drop

Key Insights Pulse Biosciences' significant insider ownership suggests inherent interests in company's expansion 69% of...

Yahoo | December 12, 2024

Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, Pulse Biosciences...

Yahoo | November 15, 2024

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

MIAMI, October 31, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of benign thyroid nodules. Dr. Stefano Spiezia presented these excellent results today at the 2024 American Thyroid Association Annual Meeting.

Yahoo | October 31, 2024

Q3 2024 Pulse Biosciences Inc Earnings Call

Q3 2024 Pulse Biosciences Inc Earnings Call

Yahoo | October 31, 2024


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!